Product Information
INFLECTRA 100 MG VIAL is a brand biologic product labeled by Pfizer Inc., priced at $491.5457 per EA under NDC 00069080901. Its NADAC has been published 26 times since Oct 23, 2024.
Strength
100 mg/10mL
Manufacturer
Pfizer Inc.NDC
00069080901
Classification
Brand Biologic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
3/19/2025
Active Ingredients
INFLIXIMABApproval Type
Biologic (BLA)
FDA Application
BLA125544On Market Since
11/21/2016
Pharmacological Classes
Price Statistics
The NADAC for INFLECTRA 100 MG VIAL has been published 26 times since Oct 23, 2024, and over the history we have for it it has declined 14.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $491.5457 per EA |
|---|---|
| All-time high | $577.3460 (Dec 11, 2024) |
| All-time low | $491.5457 (Mar 19, 2025) |
| Median price | $504.5217 |
| Average price | $524.4338 |
| Largest weekly change | -12.6% (Dec 18, 2024) |
| Weeks tracked | 26 |
| Tracking since | Oct 23, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-14.9%
Last surveyed Apr 16, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the infliximab-dyyb market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
infliximab-dyyb market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tumor Necrosis Factor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INFLECTRA 100 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for INFLECTRA 100 MG VIAL, manufactured by Pfizer Inc., is $491.5457 per EA (NDC 00069080901), effective Apr 16, 2025.
How has the price of INFLECTRA 100 MG VIAL changed over time?
Over the history we have for it, the NADAC for INFLECTRA 100 MG VIAL has declined 14.9%. It has been tracked across 26 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for INFLECTRA 100 MG VIAL?
Since Oct 23, 2024, the NADAC for INFLECTRA 100 MG VIAL has ranged from a low of $491.5457 (Mar 19, 2025) to a high of $577.3460 (Dec 11, 2024), with a median of $504.5217 per EA.
Are there cheaper alternatives to INFLECTRA 100 MG VIAL?
No other NADAC-published product currently shares the active ingredient and strength of INFLECTRA 100 MG VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures INFLECTRA 100 MG VIAL?
INFLECTRA 100 MG VIAL (NDC 00069080901) is labeled by Pfizer Inc., and CMS classifies it as a brand biologic product.